{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:56:37Z","timestamp":1792112197017,"version":"4.4.0"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We have created a precisely pegylated IL-2 [SAR-444245 (SAR\u2019245) or pegenzileukin, previously THOR-707] designed for proliferation of target CD8+ T and NK cells for anticancer activity, with minimal expansion of anti-target regulatory CD4+ T cells (Treg) that counter their action, or eosinophils that trigger vascular leak syndrome (VLS). We performed in vivo studies in nonhuman primates (NHP) to monitor the safety of SAR\u2019245, pharmacokinetic profile, and pharmacodynamic parameters including expansion of peripheral CD8+ T and NK cells, and effects on Tregs and eosinophils. Studies included multiple ascending dosing and repeat dosing with different regimens (QW, Q2W, Q3W and Q4W). We also conducted ex vivo studies using human primary cells to further evaluate SAR\u2019245 stimulation of target cells alone and in combination with programmed cell-death 1 (PD-1) checkpoint inhibitors. The pharmacokinetic profile of SAR\u2019245 in NHP demonstrated dose-proportional exposure that was comparable with redosing. It elicited expansion of peripheral CD8+ T and NK cells that was comparable with each dose and with multiple dosing regimens. Once-weekly dosing showed no significant adverse effects, including no hallmark signs of VLS at dosing levels up to 1 mg\/kg. Ex vivo, SAR\u2019245 enhanced T-cell receptor responses alone and in combination with PD-1 inhibitors without inducing cytokines associated with cytokine release syndrome or VLS. Results support the clinical development of SAR\u2019245 as a drug candidate for the treatment of solid tumors, alone or in combination with PD-1 inhibitory agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>SAR-444245 (SAR\u2019245, pegenzileukin) is an extended half-life IL-2 that targets effector CD8+ T and NK cells, with little effect on regulatory T cells. We show that in the nonhuman primate model that closely approximates human immune function and response to IL-2, SAR\u2019245 selectively activates CD8+ T and NK effectors without significant serious side effects (vascular leak syndrome or cytokine release syndrome), suggesting its potential for the treatment of solid tumors in humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0278","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T11:30:16Z","timestamp":1727263816000},"page":"2799-2814","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7350-1466","authenticated-orcid":false,"given":"Lina","family":"Ma","sequence":"first","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1121-9134","authenticated-orcid":false,"given":"Nicole V.","family":"Acuff","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7348-9138","authenticated-orcid":false,"given":"Ingrid B.","family":"Joseph","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7573-1754","authenticated-orcid":false,"given":"Jerod L.","family":"Ptacin","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6403-9350","authenticated-orcid":false,"given":"Carolina E.","family":"Caffaro","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9938-996X","authenticated-orcid":false,"given":"Kristine M.","family":"San Jose","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-2949","authenticated-orcid":false,"given":"Hans R.","family":"Aerni","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-8403","authenticated-orcid":false,"given":"Roberto","family":"Carrio","sequence":"additional","affiliation":[{"name":"2Sanofi, Orlando, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0940-7783","authenticated-orcid":false,"given":"Anthony M.","family":"Byers","sequence":"additional","affiliation":[{"name":"2Sanofi, Orlando, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4710-5444","authenticated-orcid":false,"given":"Rob W.","family":"Herman","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6233-345X","authenticated-orcid":false,"given":"Yelena","family":"Pavlova","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3558-7591","authenticated-orcid":false,"given":"Michael J.","family":"Pena","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1953-6190","authenticated-orcid":false,"given":"David B.","family":"Chen","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0084-7039","authenticated-orcid":false,"given":"Christen","family":"Buetz","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7461-7247","authenticated-orcid":false,"given":"Taylor K.","family":"Ismaili","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1833-8408","authenticated-orcid":false,"given":"Helene V.","family":"Pham","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8734-9273","authenticated-orcid":false,"given":"Margot","family":"Cucchetti","sequence":"additional","affiliation":[{"name":"3Sanofi, Vitry-sur-Seine, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5645-9111","authenticated-orcid":false,"given":"Ingrid","family":"Sassoon","sequence":"additional","affiliation":[{"name":"3Sanofi, Vitry-sur-Seine, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6511-5624","authenticated-orcid":false,"given":"Lilia K.","family":"Koriazova","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0139-9005","authenticated-orcid":false,"given":"Joseph A.","family":"Leveque","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-6718","authenticated-orcid":false,"given":"Laura K.","family":"Shawver","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8305-1393","authenticated-orcid":false,"given":"Jill M.","family":"Mooney","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-2085","authenticated-orcid":false,"given":"Marcos E.","family":"Milla","sequence":"additional","affiliation":[{"name":"1Synthorx, Inc., A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"2025040317281553600_bib1","first-page":"79","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria","year":"2015","journal-title":"Immunotargets Ther"},{"issue":"Suppl 1","key":"2025040317281553600_bib2","first-page":"S70","article-title":"High-dose aldesleukin in renal cell carcinoma: long-term survival update","volume":"3","author":"Fisher","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"2025040317281553600_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2025040317281553600_bib4","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1046\/j.1365-2141.1999.01453.x","article-title":"Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders","volume":"105","author":"Locker","year":"1999","journal-title":"Br J Haematol"},{"key":"2025040317281553600_bib5","first-page":"57","article-title":"Comparative toxicity and pathology associated with administration of recombinant IL-2 to animals","volume":"34","author":"Anderson","year":"1993","journal-title":"Int Rev Exp Pathol"},{"key":"2025040317281553600_bib6","first-page":"37","article-title":"Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals","volume":"34","author":"Harada","year":"1993","journal-title":"Int Rev Exp Pathol"},{"key":"2025040317281553600_bib7","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"key":"2025040317281553600_bib8","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood.V78.6.1538.1538","article-title":"Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer","volume":"78","author":"van Haelst Pisani","year":"1991","journal-title":"Blood"},{"key":"2025040317281553600_bib9","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"2025040317281553600_bib10","first-page":"2009","article-title":"Pharmacokinetics of recombinant interleukin 2 in humans","volume":"50","author":"Konrad","year":"1990","journal-title":"Cancer Res"},{"key":"2025040317281553600_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-017-0002-5","article-title":"Targeting IL-2: an unexpected effect in treating immunological diseases","volume":"3","author":"Ye","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"2025040317281553600_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to give new life to T cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu Rev Med"},{"key":"2025040317281553600_bib13","doi-asserted-by":"crossref","first-page":"7855808","DOI":"10.1155\/2021\/7855808","article-title":"Interleukin 2-based fusion proteins for the treatment of cancer","volume":"2021","author":"MacDonald","year":"2021","journal-title":"J Immunol Res"},{"key":"2025040317281553600_bib14","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat Commun"},{"key":"2025040317281553600_bib15","first-page":"166","article-title":"Subacute toxicity of human recombinant interleukin 2 in cynomolgus monkeys","volume":"38","author":"Hayes","year":"1988","journal-title":"J Cell Biochem"},{"key":"2025040317281553600_bib16","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z","article-title":"Clinical effects and toxicity of interleukin-2 in patients with cancer","volume":"58","author":"Lotze","year":"1986","journal-title":"Cancer"},{"key":"2025040317281553600_bib17","doi-asserted-by":"crossref","first-page":"S885","DOI":"10.1016\/j.annonc.2022.07.873","article-title":"747P Phase I study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors","volume":"33","author":"Falchook","year":"2022","journal-title":"Ann Oncol"},{"key":"2025040317281553600_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2008.02.021","article-title":"A novel approach for the generation of human dendritic cells from blood monocytes in the absence of exogenous factors","volume":"335","author":"Schanen","year":"2008","journal-title":"J Immunol Methods"},{"key":"2025040317281553600_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.1998.00036.x","article-title":"Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application","volume":"46","author":"Kirchner","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"2025040317281553600_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025040317281553600_bib21","author":"Opdivo [package insert","year":"2020"},{"key":"2025040317281553600_bib22","article-title":"An in vitro human CD8 T cell exhaustion model for the functional screening of immune checkpoint inhibitors","volume-title":"Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts)","author":"Carrio","year":"2023  14\u201319"},{"key":"2025040317281553600_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"2025040317281553600_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.1989.7.4.477","article-title":"A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma","volume":"7","author":"Dutcher","year":"1989","journal-title":"J Clin Oncol"},{"key":"2025040317281553600_bib25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.1986.4.5.815","article-title":"Eosinophilia and fluid retention in systemic administration of interleukin-2","volume":"4","author":"Kovach","year":"1986","journal-title":"J Clin Oncol"},{"key":"2025040317281553600_bib26","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00262-014-1605-0","article-title":"Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome","volume":"63","author":"Foureau","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2025040317281553600_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"2025040317281553600_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025040317281553600_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2025040317281553600_bib30","doi-asserted-by":"crossref","first-page":"jcs212092","DOI":"10.1242\/jcs.212092","article-title":"Ki-67 and condensins support the integrity of mitotic chromosomes through distinct mechanisms","volume":"131","author":"Takagi","year":"2018","journal-title":"J Cell Sci"},{"key":"2025040317281553600_bib31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2025040317281553600_bib32","doi-asserted-by":"crossref","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"2025040317281553600_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/2326-6066.CIR-20-0427","article-title":"Differential expression of CD49a and CD49b determines localization and function of tumor-infiltrating CD8+ T cells","volume":"9","author":"Melssen","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2025040317281553600_bib34","doi-asserted-by":"crossref","first-page":"eaba7918","DOI":"10.1126\/sciimmunol.aba7918","article-title":"TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells","volume":"5","author":"Sekine","year":"2020","journal-title":"Sci Immunol"},{"key":"2025040317281553600_bib35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2025040317281553600_bib36","first-page":"6521","article-title":"Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models","volume":"49","author":"Zimmerman","year":"1989","journal-title":"Cancer Res"},{"key":"2025040317281553600_bib37","doi-asserted-by":"crossref","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"},{"key":"2025040317281553600_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025040317281553600_bib39","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"key":"2025040317281553600_bib40","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1073\/pnas.84.6.1487","article-title":"Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model","volume":"84","author":"Katre","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317281553600_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.1991.33","article-title":"A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2","volume":"49","author":"Meyers","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"2025040317281553600_bib42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/1097-0142(19950815)76:4<687::AID-CNCR2820760424>3.0.CO;2-M","article-title":"The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2","volume":"76","author":"Yang","year":"1995","journal-title":"Cancer"},{"key":"2025040317281553600_bib43","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317281553600_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","article-title":"Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy","volume":"10","author":"Skrombolas","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"2025040317281553600_bib45","first-page":"1","article-title":"The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer","volume":"1","author":"Tang","year":"2009","journal-title":"Cytokine: X"},{"key":"2025040317281553600_bib46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol"},{"key":"2025040317281553600_bib47","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","article-title":"Human IL-2 mutein with higher antitumor efficacy than wild type IL-2","volume":"190","author":"Carmenate","year":"2013","journal-title":"J Immunol"},{"key":"2025040317281553600_bib48","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"2025040317281553600_bib49","doi-asserted-by":"crossref","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025040317281553600_bib50","doi-asserted-by":"crossref","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"2025040317281553600_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"2025040317281553600_bib52","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1158\/1078-0432.CCR-06-1341","article-title":"Phase I trial of BAY 50\u20134798, an interleukin-2-specific agonist in advanced melanoma and renal cancer","volume":"13","author":"Margolin","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2025040317281553600_bib53","doi-asserted-by":"crossref","first-page":"237.16","DOI":"10.4049\/jimmunol.204.Supp.237.16","article-title":"PT101: a Treg selective agonist IL-2 mutein therapy for autoimmunity","volume":"204","author":"Higginson-Scott","year":"2020","journal-title":"J Immunol"},{"key":"2025040317281553600_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease","volume":"95","author":"Peterson","year":"2018","journal-title":"J Autoimmun"},{"key":"2025040317281553600_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40257-018-0389-y","article-title":"Mechanisms of resistance to immune checkpoint blockade","volume":"20","author":"Liu","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2025040317281553600_bib56","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0278\/3500698\/crc-24-0278.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2799\/3512145\/crc-24-0278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2799\/3512145\/crc-24-0278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:31:24Z","timestamp":1743730284000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/10\/2799\/749339\/A-Precision-Engineered-Interleukin-2-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0278","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.27302169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728460","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302187","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302145","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302157","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302151","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302163","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302175","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302181","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728445","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728457","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728451","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728463","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302148","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302154","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302166","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302178","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302172","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302184","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302196","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27302160","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728448","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728454","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728466","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728472","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28728442","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7510242","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}